Try LifeScience Products:
AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
86
K
Drugs & Biologics
46
K
Targets
979
K
Organizations
925
K
/
174
K
Clinical Trials / Results
66
M
Literatures
16
M
Patents
Recent blog posts
Edgewise Therapeutics Starts Phase 2 Trial of EDG-7500 for Obstructive HCM
Latest Hotspot
3 min read
Edgewise Therapeutics Starts Phase 2 Trial of EDG-7500 for Obstructive HCM
7 May 2024
Edgewise Therapeutics has administered the initial dose to a participant in the Phase 2 CIRRUS-HCM study, evaluating EDG-7500 in patients with Obstructive Hypertrophic Cardiomyopathy (HCM).
Read →
What are immune checkpoints?
"What" Series
2 min read
What are immune checkpoints?
7 May 2024
Immune checkpoints are a class of regulatory molecules in the immune system that are expressed on immune cells such as T cells and can modulate the intensity and duration of immune responses.
Read →
Fate Therapeutics Presents Preliminary FT522 Data for Autoimmune Diseases at ASGCT
Latest Hotspot
3 min read
Fate Therapeutics Presents Preliminary FT522 Data for Autoimmune Diseases at ASGCT
7 May 2024
Fate Therapeutics Reveals FT522 Early-Stage Data on Autoimmune Disorders in a New Abstract at the ASGCT Annual Conference.
Read →
Check out our latest report
Global Drug R&D Express (Jan 2024)

Global Drug R&D Express (Jan 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 68 drugs. Among them, 2 first-to-market drugs and 3 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Dec 2023)

Global Drug R&D Express (Dec 2023)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of December, totaling 104 drugs. Among them, 2 first-to-market drugs and 5 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Global Drug R&D Express (Nov 2023)

Global Drug R&D Express (Nov 2023)

This report compiles and summarizes the basic information of all the first-to-market and special-review medicines globally in November, totaling 104. From these, 5 first-to-market medicines and 5 special-review medicines have been meticulously selected. The report provides a detailed interpretation of these medicines, covering multiple aspects such as their basic information, development status, technological barriers, mechanisms of action, clinical trials, and competitive landscape.

Who We Serve
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.